BARHL2

Across TCGA pan-cancer cohorts, BARHL2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BARHL2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BARHL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BARHL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LUSC, and SKCM are the cancer types where BARHL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.200	0.688	.002	45	view →
LUSC	OS	Median	II,III,IV	0.191	0.748	<.001	30	view →
SKCM	DFS	Median	All	0.015	0.758	<.001	9	view →
UCEC	DFS	Median	All	0.962	0.625	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BARHL2–HNSC (OS)

Open the HNSC breakdown →